Last deal

$95M

Amount

Series B

Stage

04.01.2024

Date

2

all rounds

$215M

Total amount

date founded

Financing round

General

About Company
Human Immunology Biosciences is a biotech firm that develops therapies for immune-mediated diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

HI-Bio

founded date

01.01.2021

Number of employees

Last funding type

Series B

IPO status

Private

Description

The company was founded in 2021 in San Francisco, California, and focuses on treating auto-immune, allergic and inflammatory diseases, which are often caused by dysfunctional immune system cells. HI-Bio's strategy is to modify or deplete these cells using medicines, with the aim of providing better outcomes for patients.
Contacts

Contact Email

Social url

Similar Companies
1000
Cugene

Cugene

Cugene develops innovative medicines for cancer and inflammatory disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Waltham, MA, USA
Cytonus Therapeutics

Cytonus Therapeutics

Cytonus Therapeutics is a San Diego biotech company focused on cell-based drug delivery for immune-oncology and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

6

total raised

$5.68M
Exeliom

Exeliom

Exeliom is a clinical-stage biopharmaceutical company revolutionizing healthcare by using commensal bacteria as drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

21000 Dijon, France

total rounds

5

total raised

$25.51M
AIBIOS

AIBIOS

Aibios is a biotechnology company that develops immunotherapeutics for the treatment of immunology, cancer, and gastroenterology diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Irvine, CA, USA

total rounds

2

total raised

$10.02M
M&A Details
1

Transaction name

Acquired by

Biogen

announced date

22.05.2024

price

$1.8B

Financials

Funding Rounds
2
2

Number of Funding Rounds

$215M

Money Raised

Their latest funding was raised on 04.01.2024. Their latest investor Alpha Wave Global. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Alpha Wave Global

Alpha Wave Global

Falcon Edge Capital is a venture capital and hedge fund.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

New York, NY, USA

count Of Investments

101

count Of Exists

5
ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Chicago, IL, USA

count Of Investments

356

count Of Exists

61
Jeito Capital

Jeito Capital

Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Paris, France

count Of Investments

20
Monograph Capital

Monograph Capital

Monograph Capital is a life sciences venture firm that funds and supports innovative companies in the field of life sciences.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Biotechnology, Life Science, Venture Capital

Location

London, UK

count Of Investments

9
Co-Investors
Investors
7
4

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
Alpha Wave Global

Alpha Wave Global

Falcon Edge Capital is a venture capital and hedge fund.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

New York, NY, USA

count Of Investments

101

count Of Exists

5

Chris Dimitropoulos

Arkin Holdings

Arkin Holdings

Arkin Holdings empowers breakthrough healthcare companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Herzliya, Israel

count Of Investments

22

count Of Exists

1
ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Chicago, IL, USA

count Of Investments

356

count Of Exists

61
Paul L Berns

Paul L Berns

Paul Berns, our Chairman, has served as a member of our board since 2012. Paul Berns is a self-employed consultant to the pharmaceutical industry.From March 2006 to August 2012 Paul Berns served as President and Chief Executive Officer, and member of the Board of Directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012. From July 2005 to March 2006 .Paul Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Paul Berns was president, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Paul Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and from 1990 to 2000, Paul Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company.Paul Berns has been a director of Anacor Pharmaceuticals, Inc.since June 2012, Jazz Pharmaceuticals, PLC since June 2010, and of XenoPort, Inc.since 2005. Paul Berns received a B.S. in Economics from the University of Wisconsin.

current job

Anacor Pharmaceutical
Anacor Pharmaceutical
Carol Suh

Carol Suh

Carol Suh is the co-founder and vice president, business development of Neumora, and a partner with ARCH Venture Partners. A stem cell biologist by training, Carol combines her scientific expertise with the business side of biotech.

current job

ARCH Venture Partners
ARCH Venture Partners

organization founded

1

People

Employee Profiles
8

Lorna Dean

Vice President of Clinical Operations

Christina Carlson

Christina Carlson

General Counsel

Joyce Liaw

Joyce Liaw

Vice President of Finance

Matthew Albert

Matthew Albert

Chief Translational Officer

Ariella Kelman

Senior Vice President of Development

Jaideep Dudani

Jaideep Dudani

Head of Portfolio Development

Carl Enell

Carl Enell

Chief Business Officer

Travis Murdoch

Travis Murdoch

Chief Executive Officer

Activity

Recent News
5
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week